The DPYD Test is an advanced genetic screening tool designed to evaluate risk levels associated with toxicity from 5-FU and capecitabine treatments in cancer patients. Through the assessment of the DPYD gene, which encodes the enzyme dihydropyrimidine dehydrogenase, the test identifies patients at heightened risk for serious side effects from these chemotherapies. This is especially critical for addressing adverse effects in colorectal, breast, pancreatic, and other gastrointestinal cancers.\n\nDesigned to support clinical decision-making, the DPYD Test provides a comprehensive genetic profile that includes five specific single nucleotide variants (SNVs) within the DPYD gene. These genetic insights help oncologists to personalize chemotherapy regimens, minimizing the risk of toxicity by identifying patients who may need adjusted dosages or alternative treatments.\n\nThe DPYD Test is available as an add-on to existing Tempus diagnostic tools, amplifying its utility in a clinical setting. By offering expanded toxicity risk assessment without the need for additional tissue samples, it emphasizes convenience and accuracy, ensuring safer and more effective chemotherapy management for patients with cancer.
